European Biotech Acquisition Corp. Units
EBACU
EBACU was delisted on the 2nd of March, 2023.
20 hedge funds and large institutions have $12.8M invested in European Biotech Acquisition Corp. Units in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
9% less funds holding
Funds holding: 22 → 20 (-2)
20% less capital invested
Capital invested by funds: $16M → $12.8M (-$3.21M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$110K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$29.8K |
| 3 |
Jane Street
New York
|
+$3.94K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$985 |
| 5 |
SIA
Schechter Investment Advisors
Birmingham,
Michigan
|
+$98 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$872K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$408K |
| 3 |
AGC
Angelo Gordon & Co
New York
|
-$394K |
| 4 |
WC
Wealthspring Capital
West Harrison,
New York
|
-$35.5K |
| 5 |
CCM
Condor Capital Management
Martinsville,
New Jersey
|
-$10K |
EBACU Hedge Fund Activity: Q2 2022 in Review
20 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Units (EBACU) for Q2 2022, worth a combined $12.8M — down 20% from $16M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of EBACU and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Clear Street, opening a new position worth an estimated $110K. The largest seller was Magnetar Financial, cutting an estimated $872K.
- 20 institutional investors held European Biotech Acquisition Corp. Units (EBACU) as of Q2 2022, down from 22 in Q1 2022.
- Funds reported $12.8M of European Biotech Acquisition Corp. Units stock for Q2 2022, down 20% quarter-over-quarter.
- 1 fund opened new European Biotech Acquisition Corp. Units positions in Q2 2022 and 3 closed out, a net change of -2 holders.
- The largest European Biotech Acquisition Corp. Units buyer in Q2 2022 was Clear Street, an estimated $110K added.
- The largest European Biotech Acquisition Corp. Units seller in Q2 2022 was Magnetar Financial, an estimated $872K sold.
Based on aggregated 13F filings for Q2 2022.